Legend Data on Earliest Use to Date of CARVYKTI® in Multiple Myeloma

 

• First analysis of CARTITUDE-2 Cohort D study investigating CARVYKTI® in multiple myeloma with suboptimal response after front-line ASCT featured in an oral presentation at the 2024 ASCO Annual Meeting show deep and durable responses with one-time infusion of CARVYKTI®

• Subgroup analysis from the CARTITUDE-4 study in an oral presentation at ASCO shows CARVYKTI® improved PFS vs standard therapy in a functionally high-risk population as early as second line associated with poor clinical outcomes

• Results of a CARTITUDE-4 subgroup analysis by cytogenetic risk showing the favorable efficacy results of CARVYKTI® across different cytogenetic abnormalities to be released in a poster presentation at the 2024 EHA Congress

https://www.businesswire.com/news/home/20240603474010/en/Legend-Biotech-Shares-Data-on-the-Earliest-Use-to-Date-of-CARVYKTI%C2%AE-in-the-Treatment-of-Multiple-Myeloma-and-Important-Subgroup-Analyses-at-ASCO-and-EHA